SCHEMBL716228

SCHEMBL716228

Cc1ccc(NC(=O)Nc2ccc(N(C)C)cc2)cc1Nc1nc(-c2cccnc2)cs1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 9/20 0.70
BCR P11274 8/20 0.70
NPC1 O15118 7/20 0.67
RAB9A P51151 7/20 0.67
GAA P10253 4/20 0.67
TDP1 Q9NUW8 2/20 0.67
TP53 P04637 1/20 0.67
MAPT P10636 1/20 0.67
MAPK1 P28482 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
PDGFRB P09619 2/20 0.60
HDAC3 O15379 1/20 0.60
KDR P35968 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714805 0.91 ABL1 (0.72) ABL1BCRNPC1RAB9AGAA
SCHEMBL15629425 0.91 ABL1 (0.57) ABL1BCRNPC1RAB9AGAA
SCHEMBL717044 0.91 GAA (0.74) ABL1BCRNPC1RAB9AGAA
SCHEMBL715934 0.89 GAA (0.65) ABL1BCRNPC1RAB9AGAA
SCHEMBL717030 0.89 GAA (0.65) ABL1BCRNPC1RAB9AGAA
SCHEMBL14319701 0.89 GAA (0.65) ABL1BCRNPC1RAB9AGAA
SCHEMBL5579274 0.89 GAA (0.67) ABL1BCRNPC1RAB9AGAA
SCHEMBL716370 0.87 GAA (0.63) ABL1BCRNPC1RAB9AGAA
SCHEMBL717539 0.86 GAA (0.62) ABL1BCRNPC1RAB9AGAA
SCHEMBL14286286 0.86 MEN1 (0.64) ABL1BCRNPC1RAB9AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4726486-B2 2011-07-20 JP claimed
CN-100491374-C 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2009-05-27 CN claimed
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders AB SCIENCE 2008-10-16 US claimed
US-7423055-B2 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE (FR) 2008-09-09 US claimed
EP-1525200-B1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2007-10-10 EP claimed
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2005-10-27 US claimed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN claimed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP claimed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US claimed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO claimed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN disclosed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP disclosed
WO-2004076693-A1 TAILORED TREATMENT SUITABLE FOR DIFFERENT FORMS OF MASTOCYTOSIS AB SCIENCE (FR) 2004-09-10 WO disclosed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. KIT, MAP3K2, CMA1 ABL1 251/4885BCR 678/4885NPC1 2227/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B ABL1 22/4885BCR 167/4885NPC1 2356/4885
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors KIT, CHUK, MAP3K2 ABL1 36/4885BCR 232/4885NPC1 2045/4885
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders KIT, MAP3K1, MAP3K6 ABL1 176/4885BCR 389/4885NPC1 3150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.